5 citations,
January 2022 in “Clinical cancer investigation journal” Certain Dibenzo derivatives may help treat prostate cancer.
2 citations,
November 2022 in “Biosensors” A new, efficient method has been developed to detect darolutamide and thalidomide, drugs used for certain hair loss and prostate cancer treatments, in pharmaceuticals and body fluids.
May 2024 in “Journal of molecular structure” A new compound, 3a, effectively fights prostate cancer better than finasteride.
16 citations,
October 2007 in “Andrologia” DHT is a strong androgen that may pose less risk to the prostate compared to testosterone.
Increased free testosterone can lead to stronger bones and less body fat but also higher risks of prostate cancer, hair loss, spine issues, and high blood pressure.
193 citations,
August 1985 in “Endocrinology” Different animals have unique versions of the enzyme that changes testosterone into another hormone, which is important for creating effective treatments for prostate and hair loss conditions.
56 citations,
November 2007 in “Molecular and cellular endocrinology” Two enzymes regulate androgen receptor activity, affecting treatments for androgen insufficiency and benign prostatic hyperplasia.
January 1983 in “Elsevier eBooks” Cyproterone acetate is used to treat conditions like prostate cancer, early puberty, excessive sexual drive, and female androgenization by affecting androgen functions and suppressing certain hormones.
Men with early balding may have a higher risk of prostate issues, and surgery for prostate cancer has a slight survival benefit over radiation.
February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
May 2020 in “International journal of molecular biology” Mutations in the AR gene cause hair thinning and loss.
30 citations,
July 2009 in “Experimental and clinical endocrinology & diabetes” Cyproterone acetate effectively treats sexual disorders by reducing sexual functions and is generally well-tolerated.
124 citations,
September 1992 in “Endocrinology” The human type II 5α-reductase gene, linked to certain male health conditions, has a specific structure and low similarity to other related genes.
14 citations,
November 2014 in “European journal of medicinal chemistry” Researchers found new potential treatments for conditions related to the androgen receptor, like male hormonal contraception, by testing thousands of compounds.
18 citations,
April 2001 in “Bioorganic & Medicinal Chemistry Letters” The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.
61 citations,
May 2010 in “Integrative Cancer Therapies” There is no clear recommendation for using selenium in cancer patients; it may be beneficial to correct low selenium levels before treatment.
76 citations,
September 1992 in “Endocrinology” The human type II 5α-reductase gene has a specific structure important for understanding certain medical conditions.
35 citations,
May 2012 in “Expert Opinion on Pharmacotherapy” The document concludes that there are various treatments for different types of alopecia, but more research is needed for evidence-based treatments.
2 citations,
April 2007 in “Journal of Labelled Compounds and Radiopharmaceuticals” The conclusion is that tritium-labeled testosterone metabolites can be made and are better converted into dihydrotestosterone in skin cells than in prostate tissue.
April 2015 in “The Journal of Urology” Finasteride reduces PSA levels by around 40-50% in BPH patients.
2 citations,
October 2001 in “Analytical Sciences” A new compound that could treat various androgen-related conditions was created and analyzed.
1 citations,
January 2009 in “X-ray Structure Analysis Online” A new compound was made that might help treat diseases related to male hormones.
March 2009 in “The Journal of Urology” Low dose finasteride causes only small changes in PSA levels in older men with BPH.
9 citations,
January 2018 in “Journal of the European Academy of Dermatology and Venereology” A male patient developed frontal fibrosing alopecia after antiandrogen therapy for prostate cancer.
August 2017 in “Journal of epidemiological research” Cancer rates are increasing in developed countries, with estrogen, aging, low vitamin D3, and HPV infection as common causes.
September 2009 in “European Urology Supplements” After prostate removal surgery, higher initial prostate size was linked to higher urethral PSA levels and more severe male pattern baldness.
January 2016 in “Hair transplant forum international” Finasteride's link to health issues like male breast cancer, infertility, and prostate cancer needs more research through placebo-controlled trials to confirm.
14 citations,
August 2021 in “Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy” Metformin, a diabetes drug, may help prevent and treat various cancers, but more research is needed.
1 citations,
January 2013 in “MedChemComm” PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
10 citations,
December 2014 in “PubMed” Finasteride, a hair loss drug, may cause sexual dysfunction and depression, but these effects are usually temporary and the drug is generally safe. More research is needed.